NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
6/8 — Strong
NAMENDA XR (memantine hydrochloride) by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for alzheimer's disease. First approved in 2010.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA XR is an extended-release oral capsule containing memantine hydrochloride, an NMDA receptor antagonist indicated for Alzheimer's disease, frontotemporal dementia, and hepatocellular carcinoma. The drug works by blocking glutamate-mediated excitotoxicity at NMDA receptors, though it does not prevent or slow neurodegeneration.
$2MPart D
Peak3.4 years to LOEProduct is at peak lifecycle stage with modest Medicare spend ($2M, 2,850 claims in 2023), indicating a mature, stable franchise with limited growth headroom.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Indications (1)
Clinical Trials (2)
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Started Jun 2013
3,482 enrolled
Alzheimer's Desease
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Started Jul 2008
42 enrolled
Down Syndrome
Worked on NAMENDA XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.